You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Towards a New Generation of Glycoengineered Pneumococcal Bioconjugate Vaccines
SBC: VaxNewMO Topic: NIAIDPROJECT SUMMARY Pneumococcal pneumonia remains the leading cause of bacterial pneumonia in both children under years of age and adults over years of age The standard preventative therapy is the conjugate vaccine Prevnar which consists of an immunogenic carrier protein covalently attached to one of thirteen pneumococcal capsular polysaccharides Although Prevnar has significantly red ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
SA FasL engineered human islets as a novel product for the treatment of type diabetes
SBC: FasCure Therapeutics LLC Topic: NIDDKPROJECT SUMMARY Type diabetes T D is a chronic autoimmune disorder that affects of population worldwide Exogenous insulin treatment is the standard of care for T D but often negatively affects the quality of life and is ineffective in preventing recurrent hyperglycemia episodes and chronic complications Recent studies show that human islet allografts can restore long term normoglycemia ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
ErythroMer Nanoscale Bio Synthetic Red Cell Substitute
SBC: KaloCyte Inc Topic: NHLBIPROJECT SUMMARY There is need for an artificial oxygen O carrier to substitute for banked blood in settings where stored blood is unavailable pre hospital care transport austere environments undeveloped countries or undesirable transfusion risk exceeds benefit To address this need we developed ErythroMer EM a first in class nano cyte blood substitute EM is a deformable ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Enabling point of care molecular diagnostics by developing an adaptive PCR instrument and on demand kit reagents
SBC: BIOVENTURES, INC Topic: 172Because of its high sensitivity polymerase chain reaction PCR is the gold standard for the diagnosis of many infectious diseases but generally only implemented in well equipped laboratories One of the major roadblocks for expanding PCR to point of care markets is the lack of simple robust single tube PCR designs which preserve its laboratory based high sensitivity and specificity In this F ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
TheraBracelet: The first and only wearable to instantly improve stroke hand function
SBC: TheraBracelet, Inc. Topic: NICHDProject SummaryPost stroke hand impairment is highly prevalent and severely restricts functional ability and independenceIn facteveryseconds a new stroke occursand stroke is recognized as the leading cause of long term disabilityYetthere is no assistive device to help hand function at homeevery dayduring activities of daily livingExisting devices such as hand opening orthoses are expensivee gMyomo ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Develop a new cisplatin based drug combination with reduced ototoxicity
SBC: GATEWAY BIOTECHNOLOGY, INC. Topic: NIDCDPROJECT SUMMARY In spite of recent new drug developments platinum based drugs such as cisplatin are still widely used to treat solid organ malignancies Besides its limited efficacy serious side effects have been associated with the use of cisplatin such as bilateral and irreversible hearing loss In the cochlea cisplatin can trigger the production of reactive oxygen species and activate sev ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Developing a Nutraceutical Product against Noise Induce Hearing Loss
SBC: GATEWAY BIOTECHNOLOGY, INC. Topic: NIDCDPROJECT SUMMARY The most common occupational and environmental hazard in this country is noise Itandapos s not surprising then that noise induced hearing loss NIHL is the second most common form of sensorineural hearing deficit behind only age related hearing loss presbycusis Although therapeutics that target the free radical pathway have shown promise for reducing NIHL there are no effe ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Commercialization of a Novel Therapeutic for Alzheimer's Disease
SBC: CoPlex Therapeutics, LLC Topic: NIAABSTRACT Traditional mon therapeutictarget driven approaches to drug development for Alzheimer s diseaseADare becoming increasingly expensive and in many cases disappointingly unsuccessfulBased on preliminary in vitro and in vivo studies we have identified a novel small moleculemethyldimethyloxodihydrobenzo cnaphthyridinecarboxylateBNCthat significantly decreases neuroinflammation and production o ...
STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Enabling point-of-care molecular diagnostics by developing an adaptive PCR instrument and on-demand kit reagents
SBC: BIOVENTURES, INC Topic: 172Because of its high sensitivitypolymerase chain reactionPCRis the gold standard for the diagnosis of many infectious diseasesbut generally only implemented in well equipped laboratoriesOne of the major roadblocks for expanding PCR to point of care markets is the lack of simplerobustsingle tube PCR designs which preserve its laboratory based high sensitivity and specificityIn this Fast Track STTR a ...
STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Development of Fibrin Specific Nuclear Probe to Reduce LVAD Adverse Events
SBC: CAPELLA IMAGING, LLC Topic: NHLBIDespite the myriad major advances in cardiology the prognosis for patients with severe medically refractive heart failure HF is exceedingly poor Approximately deaths occur annually in patients with HF who have endured an impaired quality of life often accompanied by significant economic and personal losses due to recurrent hospitalizations At least of these deaths were directl ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health